Trade Summary

2 days ago, Ben-Noon Alon, serving as Chief Executive Officer at NeuroSense Therapeutics Ltd. (NRSN), purchased 250,000 shares at $0.80 per share, for a total transaction value of $200,000.00. Following this transaction, Ben-Noon Alon now holds 4,534,233 shares of NRSN.

This purchase represents a 5.84% increase in Ben-Noon Alon's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, June 16, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, June 17, 2026 at 4:30 PM ET, 1 day after the trade was made.